CERO THERAPEUTICS HOLDINGS, INC. (CERO): debt financing — CERo Therapeutics issues $437,500 convertible note to Keystone Capital Partners, 10% interest, due 2027

CERO THERAPEUTICS HOLDINGS, INC.

Issued to Keystone Capital Partners a convertible note with purchase price $350,000 and face value $437,500.
Note bears interest at 10% per annum, matures April 9, 2027, with up to $1,000,000 total borrowing capacity.
Conversion price is lesser of $0.05 or 80% of avg of 5 lowest intraday prices in 20 days prior to conversion.
Beneficial ownership limitation of 4.99% applies; issuance exempt from registration under Section 4(a)(2).

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $350,000 with Keystone Capital Partners, LLC at 10% per annum maturing April 9, 2027.

Instrument: convertible notes
Principal: $350,000
Counterparty: Keystone Capital Partners, LLC
Rate: 10% per annum
Maturity: April 9, 2027
Event: incurrence

Exact text from the filing

On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face value of $437,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for purchase price of $350,000.

Security: convertible note
Purchaser: Keystone Capital Partners, LLC
Consideration: purchase price of $350,000

Exact text from the filing

On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face value of $437,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. entered into Note with Keystone Capital Partners, LLC valued at $350,000 (effective 2026-04-08).

Action: entry
Agreement: notes offering
Counterparty: Keystone Capital Partners, LLC
Value: $350,000
Effective: 2026-04-08

Exact text from the filing

On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face value of $437,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-043519

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.